Title	Efficacy endpoints
Number of patients screened	17
Number of patients enrolled	17
Number of patients evaluable for toxicity	17
Number of patients evaluated for efficacy	16
Evaluation method	RECIST 1.1
Response assessment, PR	1 (6.3%)
Response assessment, SD	9 (56.3%)
Response assessment, PD	6 (37.5%)
(Median) duration assessments, OS	15.3 months (95% CI, 3.1-not reached)
(Median) duration assessments, PFS	3.2 months (95% CI, 1.2-7.4
(Median) duration assessments, TTF	3.2 months (95% CI, 1.2-not reached)
Outcome notes	The 1-year survival rate (the primary endpoint of this study) was 53.3% (95% CI, 25.9-74.6) (Table 1). The ORR and disease control rate were 6.3% (95% CI, 0.2-30.2) and 62.5% (95% CI, 35.4-84.8), respectively.